# Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Source: https://onco.cc/trials/nct06050122/  
OnCo record `nct06050122` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Patidegib Topical Gel in basal cell carcinoma, run by Sol-Gel Technologies, Ltd., now completed.

## Summary

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome is a phase 3 interventional study registered as NCT06050122 by Sol-Gel Technologies, Ltd., with 140 participants enrolled, started 2024-03-17 and reached its primary completion in 2026-08-20. Interventions recorded: Patidegib Topical Gel and Patidegib Topical Gel with no active patidegib.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06050122
- Phase: 3
- Setting: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome
- Sponsor: Sol-Gel Technologies, Ltd.
- Enrolled: 140

## Notes

- Registry status on 22 September 2026: Completed (registry record last updated 18 September 2026; primary completion reached 20 August 2026).

## Sources

- ClinicalTrials.gov NCT06050122: https://clinicaltrials.gov/study/NCT06050122

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/), [Locally advanced and metastatic basal cell carcinoma](https://onco.cc/cancers/locally-advanced-bcc/)
- drugs: [Patidegib](https://onco.cc/drugs/patidegib/)
- terms: [Why people stop taking hedgehog inhibitors](https://onco.cc/terms/hedgehog-inhibitor-tolerability/)
- trials: [Patidegib gel in Gorlin syndrome (phase 2A)](https://onco.cc/trials/patidegib-gel-gorlin-phase-2/), [STEVIE (vismodegib in ordinary practice)](https://onco.cc/trials/stevie/)

---
JSON: https://onco.cc/api/v1/entities/nct06050122.json